Agomab Therapeutics NV (?Agomab') today announced positive interim results from 44 patients completing treatment in the ongoing STENOVA1 Phase 2a clinical trial for AGMB-129, an oral gastro-intestinal ...

If sufficiently large, a gallstone may lodge at the narrowest part of the gastrointestinal tract, usually the terminal ileum, and present with small ... no evidence of either a benign or malignant ...

AGMB-129 hit all primary and secondary endpoints in interim read-out from 44 patients after 12 weeks treatment -- -- Detailed interim STENOVA results to be presented at future scientific conference ...

We are at a critical time and supporting climate journalism is more important than ever. Science News and our parent organization, the Society for Science, need your help to strengthen ...